This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Carlo and Baker cover the big races to watch on this off-cycle Election Day, the concrete pledges starting to come out of COP26, Jeffrey Epstein keeps causing CEOs to lose their jobs, and Ryan Murphy's TV hit that wasn't.
The UN climate change conference kicked off on Sunday with about 120 world leaders and delegates gathering in Glasgow, Scotland this week, as experts continue to warn about the harms of heightened emissions and the effects on climate change. The topic of ESG investing is expected to be a top priority at the summit. Jefferies global head of ESG and sustainability research Aniket Shah joined Cheddar News' Closing Bell to discuss.
Christian Kroll, CEO of Ecosia, joins 'Fast Forward' to discuss how Ecosia uses its ad revenue to plant trees, and what the company plans to do after launching a $405 million venture capital fund focused on combating the climate crisis.
Dr. Ashley McClure, co-founder of Climate Health Now, joins 'Fast Forward' to discuss why the climate crisis is the greatest threat to humanity and health, and measures we need to take to reverse course.
Clinical research company Medable has secured $304 million in Series D funding, marking its fourth round since 2020, giving the firm a valuation of just over $2 billion. Dr. Michelle Longmire, CEO and Co-founder, Medable joined Cheddar's Opening Bell to discuss the future of the company.
The National Hurricane Center announced that the list of storm names in 2021 has been exhausted as one of the most active hurricane seasons in history continues to stir in the Atlantic Ocean. Subtropical Storm Wanda marks only the third time in history (last year being the second) that all the names were used in a single season.
Astronomers at NASA have located what could be the first exoplanet not only outside of the solar system but outside of our own galaxy in the Messier 51 (or the Whirlpool Galaxy), 28 million light-years away. It could take astronomers up to 70 years to see if the planet passes in front of its star to verify the find.
Even with pandemic lockdowns, greenhouse gas levels reached new highs in 2020, according to the World Meteorological Organization. This report comes just a week ahead of the United Nations Climate Change Conference, otherwise known as Cop26. Shannon Osaka, climate policy and solutions reporter at Grist, joined Cheddar's Between Bells to discuss.
Oatly Chief Sustainability Officer, Ashley Allen joins Cheddar News to talk about food waste and hows its been left off the table in the upcoming COP26 agenda. Ashley will be on the ground at COP26 and advocating for this conversation to get the attention it deserves.
Carlo's flying solo today, talking COP26 and climate change, another racially charged trial gets underway, SCOTUS takes on abortion and a stunning rise in traffic deaths points to a bigger societal breakdown sparked by the pandemic.
